These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 35822094)

  • 21. Increased prevalence of Parkinson's disease in alkaptonuria.
    Ranganath L; Khedr M; Milan AM; Davison AS; Norman BP; Janssen MCH; Lock E; Bou-Gharios G; Gallagher JA
    JIMD Rep; 2023 Jul; 64(4):282-292. PubMed ID: 37404676
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interference of hydroxyphenylpyruvic acid, hydroxyphenyllactic acid and tyrosine on routine serum and urine clinical chemistry assays; implications for biochemical monitoring of patients with alkaptonuria treated with nitisinone.
    Curtis SL; Norman BP; Milan AM; Gallagher JA; Olsson B; Ranganath LR; Roberts NB
    Clin Biochem; 2019 Sep; 71():24-30. PubMed ID: 31228435
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ochronotic osteoarthropathy in a mouse model of alkaptonuria, and its inhibition by nitisinone.
    Preston AJ; Keenan CM; Sutherland H; Wilson PJ; Wlodarski B; Taylor AM; Williams DP; Ranganath LR; Gallagher JA; Jarvis JC
    Ann Rheum Dis; 2014 Jan; 73(1):284-9. PubMed ID: 23511227
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comprehensive Biotransformation Analysis of Phenylalanine-Tyrosine Metabolism Reveals Alternative Routes of Metabolite Clearance in Nitisinone-Treated Alkaptonuria.
    Norman BP; Davison AS; Hickton B; Ross GA; Milan AM; Hughes AT; Wilson PJM; Sutherland H; Hughes JH; Roberts NB; Bou-Gharios G; Gallagher JA; Ranganath LR
    Metabolites; 2022 Sep; 12(10):. PubMed ID: 36295829
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metabolomic studies in the inborn error of metabolism alkaptonuria reveal new biotransformations in tyrosine metabolism.
    Norman BP; Davison AS; Hughes JH; Sutherland H; Wilson PJ; Berry NG; Hughes AT; Milan AM; Jarvis JC; Roberts NB; Ranganath LR; Bou-Gharios G; Gallagher JA
    Genes Dis; 2022 Jul; 9(4):1129-1142. PubMed ID: 35685462
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adequacy of nitisinone for the management of alkaptonuria.
    Abbas K; Basit J; Rehman MEU
    Ann Med Surg (Lond); 2022 Aug; 80():104340. PubMed ID: 36045846
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of nitisinone in patients with alkaptonuria.
    Suwannarat P; O'Brien K; Perry MB; Sebring N; Bernardini I; Kaiser-Kupfer MI; Rubin BI; Tsilou E; Gerber LH; Gahl WA
    Metabolism; 2005 Jun; 54(6):719-28. PubMed ID: 15931605
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Frequency, diagnosis, pathogenesis and management of osteoporosis in alkaptonuria: data analysis from the UK National Alkaptonuria Centre.
    Ranganath LR; Khedr M; Vinjamuri S; Gallagher JA
    Osteoporos Int; 2021 May; 32(5):927-938. PubMed ID: 33118050
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nutritional interventions for patients with alkaptonuria: A minireview.
    Imrich R; Zatkova A; Lukacova O; Sedlakova J; Zanova E; Vlcek M; Penesova A; Radikova Z; Havranova A; Ranganath L
    Endocr Regul; 2023 Jan; 57(1):61-67. PubMed ID: 36966367
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of nitisinone on homogentisic acid and tyrosine: a two-year survey of patients attending the National Alkaptonuria Centre, Liverpool.
    Milan AM; Hughes AT; Davison AS; Devine J; Usher J; Curtis S; Khedr M; Gallagher JA; Ranganath LR
    Ann Clin Biochem; 2017 May; 54(3):323-330. PubMed ID: 28081634
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum markers in alkaptonuria: simultaneous analysis of homogentisic acid, tyrosine and nitisinone by liquid chromatography tandem mass spectrometry.
    Hughes AT; Milan AM; Davison AS; Christensen P; Ross G; Gallagher JA; Dutton JJ; Ranganath LR
    Ann Clin Biochem; 2015 Sep; 52(Pt 5):597-605. PubMed ID: 25628464
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Urine homogentisic acid and tyrosine: simultaneous analysis by liquid chromatography tandem mass spectrometry.
    Hughes AT; Milan AM; Christensen P; Ross G; Davison AS; Gallagher JA; Dutton JJ; Ranganath LR
    J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Jul; 963():106-12. PubMed ID: 24952314
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical and biochemical assessment of depressive symptoms in patients with Alkaptonuria before and after two years of treatment with nitisinone.
    Davison AS; Harrold JA; Hughes G; Norman BP; Devine J; Usher J; Hughes AT; Khedr M; Gallagher JA; Milan AM; J C G H; Ranganath LR
    Mol Genet Metab; 2018 Sep; 125(1-2):135-143. PubMed ID: 30049652
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of Phenylalanine- and Tyrosine-Restricted Diet in Alkaptonuria Patients on Nitisinone Treatment: Case Series and Review of Literature.
    Teke Kisa P; Eroglu Erkmen S; Bahceci H; Arslan Gulten Z; Aydogan A; Karalar Pekuz OK; Yuce Inel T; Ozturk T; Uysal S; Arslan N
    Ann Nutr Metab; 2022; 78(1):48-60. PubMed ID: 34736252
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patient-reported outcomes and functional assessments of patients with Alkaptonuria in a 3-year Nitisinone treatment trial.
    Spears KR; Rossignol F; Perry MB; Kayser MA; Suwannarat P; O'Brien KE; Bryant JC; Greenwood WF; Fuller S; Gahl WA; Introne WJ
    Mol Genet Metab; 2024; 143(1-2):108562. PubMed ID: 39121793
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum Amino Acid Profiling in Patients with Alkaptonuria Before and After Treatment with Nitisinone.
    Davison AS; Norman BP; Smith EA; Devine J; Usher J; Hughes AT; Khedr M; Milan AM; Gallagher JA; Ranganath LR
    JIMD Rep; 2018; 41():109-117. PubMed ID: 29754208
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of the serum metabolome of patients with alkaptonuria before and after two years of treatment with nitisinone using LC-QTOF-MS.
    Davison AS; Norman BP; Ross GA; Hughes AT; Khedr M; Milan AM; Gallagher JA; Ranganath LR
    JIMD Rep; 2019 Jul; 48(1):67-74. PubMed ID: 31392115
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Determinants of tyrosinaemia during nitisinone therapy in alkaptonuria.
    Ranganath LR; Milan AM; Hughes AT; Davison AS; M K; Norman BP; Bou-Gharios G; Gallagher JA; Imrich R; Arnoux JB; Rudebeck M; Olsson B
    Sci Rep; 2022 Sep; 12(1):16083. PubMed ID: 36167967
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Homogentisic acid is not only eliminated by glomerular filtration and tubular secretion but also produced in the kidney in alkaptonuria.
    Ranganath LR; Milan AM; Hughes AT; Khedr M; Davison AS; Shweihdi E; Norman BP; Hughes JH; Bygott H; Luangrath E; Fitzgerald R; Psarelli EE; van Kan C; Laan D; Olsson B; Rudebeck M; Mankowitz L; Sireau N; Arnoux JB; Le Quan Sang KH; Jarvis JC; Genovese F; Braconi D; Santucci A; Zatkova A; Glasova H; Stančík R; Imrich R; Rhodes NP; Gallagher JA
    J Inherit Metab Dis; 2020 Jul; 43(4):737-747. PubMed ID: 31609457
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of Melanin-like Pigment Synthesized from Homogentisic Acid, with or without Tyrosine, and Its Implications in Alkaptonuria.
    Taylor AM; Vercruysse KP
    JIMD Rep; 2017; 35():79-85. PubMed ID: 27943071
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.